Katherine J. Adams

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Brian Cameron, Andrew B. Gerry, Joseph Dukes et al. · Science Translational Medicine · 2013 · 660 citations · Full text

Monoclonal TCR-redirected tumor cell killing

Nathaniel Liddy, Giovanna Bossi, Katherine J. Adams et al. · Nature Medicine · 2012 · 312 citations

Cancer Immunosurveillance, Medicine, Tumor Immunity +3

Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition

David K. Cole, Emily S.J. Edwards, Katherine K. Wynn et al. · The Journal of Immunology · 2010 · 130 citations · Full text

T-regulatory Cell, Immunology, Alter Tcr Binding +19

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

Emmet McCormack, Katherine J. Adams, Namir J. Hassan et al. · Cancer Immunology Immunotherapy · 2012 · 96 citations · Full text

Lage-1-positive Tumors, Gfp Fluorescence Readout, Immunology +19

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

Jane Harper, Katherine J. Adams, Giovanna Bossi et al. · PLoS ONE · 2018 · 82 citations · Full text

Cell Therapy, Immunology, Immunoediting +20